Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Colorcon
Citi
Chinese Patent Office
US Army
AstraZeneca

Generated: March 20, 2019

DrugPatentWatch Database Preview

Smithkline Beecham Company Profile

« Back to Dashboard

What is the competitive landscape for SMITHKLINE BEECHAM, and when can generic versions of SMITHKLINE BEECHAM drugs launch?

SMITHKLINE BEECHAM has six approved drugs.

There are two US patents protecting SMITHKLINE BEECHAM drugs.

There are fifty patent family members on SMITHKLINE BEECHAM drugs in sixteen countries.

Summary for Smithkline Beecham
International Patents:50
US Patents:2
Tradenames:6
Ingredients:6
NDAs:6
Drug Master File Entries: 2
Patent Litigation for Smithkline Beecham: See patent lawsuits for Smithkline Beecham

Drugs and US Patents for Smithkline Beecham

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Smithkline Beecham AXID nizatidine CAPSULE;ORAL 019508-002 Apr 12, 1988 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Smithkline Beecham AXID nizatidine CAPSULE;ORAL 019508-001 Apr 12, 1988 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-004 Oct 20, 2006 AB RX Yes No 8,101,209*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Smithkline Beecham DYNACIRC isradipine CAPSULE;ORAL 019546-001 Dec 20, 1990 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-001 Oct 20, 2006 AB RX Yes No 8,101,209*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Smithkline Beecham RELAFEN nabumetone TABLET;ORAL 019583-002 Dec 24, 1991 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Smithkline Beecham

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-004 Oct 20, 2006 6,022,562*PED ➤ Try a Free Trial
Smithkline Beecham AXID nizatidine CAPSULE;ORAL 019508-001 Apr 12, 1988 4,382,090 ➤ Try a Free Trial
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-003 Oct 20, 2006 6,022,562*PED ➤ Try a Free Trial
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-002 Sep 14, 1995 4,503,067*PED ➤ Try a Free Trial
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-001 Sep 14, 1995 4,503,067*PED ➤ Try a Free Trial
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-001 Oct 20, 2006 4,503,067*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SMITHKLINE BEECHAM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 10 mg and 20 mg ➤ Subscribe 2008-03-18
➤ Subscribe Extended-release Capsules 80 mg ➤ Subscribe 2007-11-19
➤ Subscribe Capsules 1 g ➤ Subscribe 2008-11-10
➤ Subscribe Extended-release Capsules 40 mg ➤ Subscribe 2007-12-21
➤ Subscribe Oral Solution 15 mg/mL ➤ Subscribe 2008-05-14
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Teva
Mallinckrodt
Citi
Boehringer Ingelheim
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.